AsianScientist (Apr. 10, 2015) – Curiox Biosystems, a spin-off company from the Agency for Science, Technology and Research (A*STAR), has announced collaborations with two A*STAR institutes to validate the Curiox Biosystems DropArray system, a novel technology developed to make immunomonitoring more cost-efficient.
The first collaboration is with the Singapore Immunology Network (SIgN), which implemented the Curiox Biosystems DropArray system on the institute’s clinical immunomonitoring platform to validate the utility of the technology in Luminex® assays. Luminex assays use color-coded beads to multiplex up to 500 unique bioassays within a single sample, enabling scientists to simultaneously measure multiple analytes.
Researchers showed a five-fold miniaturization of Luminex assays with respect to expensive assay reagent volumes and clinical sample usage. The team at SIgN has also been executing their clinical assays on the system, achieving 65 percent savings in overall assay costs as well as reducing the usage of valuable clinical samples.
“The strikingly reduced cost and sample requirements for the DropArray system have enabled us to generate much more data with significant cost savings for the platform and consequently for our collaborators,” said Professor Laurent Renia, Executive Director of SIgN.
The second collaboration is with Dr. Frederic Bard, Senior Principal Investigator of A*STAR’s Institute of Molecular and Cellular Biology (IMCB). Bard’s laboratory has established a genome-wide RNAi screening program, focused on membrane trafficking regulation, Golgi organization and Golgi signaling to control protein glycosylation in health and diseases. His team has been optimizing the DropArray system for RNA transfection with suspension cells.
“Our DropArray technology expands the utility of multiplex analysis by enabling analytes to be screened in as little as 10μl well. The results from these collaborations demonstrate that the DropArray system is a critical next-generation tool for the expanded adoption of bead-based assays,” notes Dr. Kim Namyong, CEO of Curiox Biosystems, who has been managing these collaborations.
The Curiox washing station and DropArray microplates have been utilized in multiplexing assays, suspension cell assays, high content assays and iPS/stem cell and differentiation cell assays. The system provides users with significant reductions in bead volumes without compromising performance, while integrating seamlessly into current laboratory workflows.
———
Source: Curiox Biosystems.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
